finance.biggo.comOct 13$JNJ

JNJ Q3 FY2026 earnings call — BigGo Finance

Johnson & Johnson (JNJ) reported Q3 2026 operational sales growth of 6% to $25.4B, exceeding estimates. Full-year guidance raised to $100.7B-$101.2B. Adjusted EPS $2.59, down 7.5% YoY due to $7B in charges. Innovative Medicine grew 7.9%, while MedTech lagged at 2.5%. Management expects 2027 growth and a DePuy Synthes spin-off mid-2027.

Original reporting

finance.biggo.com

Published Oct 13, 2026, 2:54 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 13, 2026, 9:43 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$JNJ

Bullish

high confidence

Mentioned

$JNJ

Relevance

9/10

AlphAI data visualization · based on finance.biggo.com

Decision brief

The 30-second read

$JNJBullishMed

Why it matters

The key tradable items are the raised full-year adjusted operational EPS guidance, the magnitude of talc and transaction-related expense/dilution, and the segment mix shift toward Innovative Medicine strength.

Market read

Traders can update positioning based on the raised EPS outlook and the stated 2027 path, while monitoring MedTech weakness and ex-U.S. headwinds.

What to watch

The article flags potential 2027 currency headwinds and ongoing MedTech procurement and competitive pressures, which may limit multiple expansion even with raised EPS guidance.

Relevance 9/10Novelty 8/10Timing: during/after the Q3 FY2026 earnings call on 10/13/2026

Background

This is an earnings-call style recap for Johnson & Johnson’s Q3 FY2026 results, including segment performance, pipeline/commercial milestones, and full-year guidance.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JNJBullishHigh confidence

Context

JNJ reported Q3 2026 operational sales growth of 6% to $25.4B and raised full-year adjusted operational EPS guidance to $10.95-$11.05.

Expected impact

Likely upward bias as the market prices in higher full-year EPS and continued oncology and immunology momentum despite MedTech headwinds.

Evidence & confidence

The article includes specific, company-issued Q3 results plus a raised full-year EPS range, with clear drivers (Innovative Medicine strength, MedTech underperformance, and talc/transaction charges).

Market effects

Sector

Reinforces the market narrative that large-cap pharma growth is increasingly driven by oncology and immunology launches, while MedTech remains a relative drag.

Regional

U.S. outperformance (sales +9.1%) versus ex-U.S. (+1.8%) may influence regional healthcare demand expectations.

Global

Guidance and expense commentary (talc resolution, acquisitions, currency headwind) can affect broader sentiment toward U.S.-listed diversified healthcare earnings durability.

Counterpoint

What could challenge this read

The EPS beat is heavily influenced by one-time charges and transaction-related dilution; MedTech underperformance and ex-U.S. weakness could reassert pressure into 2027.

Key entities

company
Johnson & Johnson
Reported Q3 2026 operational sales growth, raised full-year adjusted operational EPS guidance, and discussed talc litigation resolution and recent acquisitions/collaborations.

Read at source ← All news

$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.comNov 4

$JNJMedAI 8/10

Johnson & Johnson’s Javelin Catheter Met Both Trial Goals and Its Impella Data Pushed Back on a Negative Study. Here’s What It Doesn’t Settle

Johnson & Johnson (JNJ) reported positive results for its Javelin catheter, meeting both primary goals in a pivotal study. Impella heart pump data showed lower death rates than a previous negative study. Javelin is still under FDA review, and Impella's recovery depends on future trials. JNJ's cardiovascular unit saw a sales decline, with Impella contributing 1.6% of total revenue. Analysts project a ~25% total return for JNJ stock.

finance.yahoo.comNov 2

$JNJMed

TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland

Johnson & Johnson's TREMFYA (guselkumab) has been approved for reimbursement in Ireland for treating moderately to severely active Crohn’s disease and ulcerative colitis. The approval is based on Phase 3 trials showing significant clinical remission rates. According to the company, it offers a novel dual mechanism of action and improved outcomes for patients.

imt.ieNov 2

$JNJMed

J&J data show lower mortality with Impella in HRPCI than CHIP-BCIS3

Johnson & Johnson (J&J) presented data at a symposium showing lower mortality rates in high-risk PCI patients using Impella heart pumps compared to the CHIP-BCIS3 trial. Three analyses, involving 1,379 patients, reported 30-day mortality rates of 6.1% and 4.7%, and 90-day rates of 6.5%. J&J's heart recovery chief medical officer highlighted the importance of device usage and patient selection. The company continues studying Impella, with PROTECT IV trial results expected in 2027.

medicaldevice-network.comNov 2

$JNJMedAI 8/10

J&J's Javelin Meets Pivotal Coronary Study Goals; Highlights Impella Survival Data At TCT

Johnson & Johnson (JNJ) reported that its Shockwave Javelin coronary catheter met primary endpoints in the FORWARD CAD study, with 93.6% successful lesion crossing and 93.4% safety. The study involved 158 patients. Separately, J&J shared favorable Impella data from three analyses, showing low mortality rates. JNJ closed at $273.20, down 0.73%.

rttnews.comNov 2

$JNJHigh

PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer

A substudy of the phase 3 PROTEUS trial, presented at ESMO Congress 2026, showed that perioperative apalutamide plus ADT reduced recurrence or death risk by 62% in high-risk prostate cancer patients. The study, supported by Johnson & Johnson, met primary endpoints, including event-free survival and metastasis-free survival. Lead author Alberto Briganti suggested the treatment could become a standard option for eligible patients.

endocrinologyadvisor.comNov 2